Biohedge Weekly
Biohedge Weekly summarizes SEC Schedule 13D/13G filings from biotech-focused hedge funds. We track 17 institutional investors with known biotech expertise.
RxDataLab builds focused data tools for agile BD, strategy, and research teams. We can filter this report for your coverage, whether by sector, specific funds, or the tickers you follow.
Weekly Filing Volume
This week 2 institutional investors disclosed positions in 4 biotech companies via SEC Schedule 13D/13G filings. 1 new position. 3 activist filings.
Filings This Week
| Company | Fund | Ownership | Type |
|---|---|---|---|
| TRINITY BIOTECH (TRIB) | Perceptive Advisors | 9.9% | 13D/A |
| SAB BIOTHERAPEUTICS INC (SABS) | Perceptive Advisors | 7.3% | New 13G |
| Cogent Biosciences, Inc. (COGT) | Fairmount Funds Management LLC | 9.9% | 13D/A |
| Apogee Therapeutics, Inc. (APGE) | Fairmount Funds Management LLC | 10.0% | 13D/A |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company’s shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses >5% ownership in a company for the first time.
We track 17 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC